Published on 25 May 2023

Vietnam Pediatric Association and Roche pledge to enhance access to care for children with Type 1 diabetes under the Changing Diabetes® in Children programme

  • The partnership will provide diabetes monitoring and management kits for 2,600 underprivileged children with Type 1 diabetes (T1D) in Vietnam, which is the entire population of children and young people with T1D in Vietnam.¹
  • In addition, it will provide education and training to doctors and nurses, and improve awareness about diabetes and its management among children with T1D and their families. 

Hanoi, Vietnam, May 25, 2023: The Vietnam Pediatric Association (VPA) and Roche Diabetes Care Vietnam, represented by Roche Vietnam Company Limited (Roche), today signed a cooperation agreement to enhance access to care for underprivileged children living with Type 1 diabetes in Vietnam. This partnership is part of a broader global collaboration between Novo Nordisk and Roche under the Changing Diabetes® in Children (CDiC) programme. Changing Diabetes® in Children is a collaborative led by Novo Nordisk and Roche Diabetes Care, which also involves other global and local partners. This public-private partnership programme aims to broaden access and create sustainable care structures in under-resourced countries. Moreover,  it provides life-saving insulin and diabetes management supplies to children and young people living with T1D up to 25 years of age.

Under the scope of this newly signed collaboration, the CDiC programme aims to enhance the quality of care for children with T1D in Vietnam by providing education and training for doctors and nurses, and boosting awareness about diabetes and its management among children with T1D and their families. The programme will also drive sustainable ways to integrate programme components into the national healthcare system. As part of the programme, VPA and Roche will provide free diabetes monitoring and management kits, including blood glucose meters, test strips, and lancets. The partnership will extend care to 2,600 children and adolescents with diabetes through the Vietnam National Children’s Hospital (VNCH) and other hospitals nationwide, covering urban and rural areas.

Vietnam is home to almost four million¹ adults with diabetes, where 51.5%¹ of the diabetes population remain undiagnosed. Furthermore, an estimated 39,500² children and adolescents under the age of 20 are living with T1D in Asia’s emerging markets. This data highlights the urgent need for awareness, early diagnosis, access to medication and management solutions to treat this chronic condition through building accessible and sustainable healthcare structures.

Assoc. Prof. PhD. Tran Minh Dien, President of the Vietnam Pediatric Association and Director of National Children's Hospital, said “Through this partnership, the VPA aims to relieve the financial and emotional burden of living with diabetes for the families of children with Type 1 diabetes. I hope many more children will experience the life-changing impact of having the necessary diabetes management tools to manage their condition well.”   

Mr. Mihai Irimescu, Cluster Head of Asia Emerging Markets, Roche Diabetes Care, said “Pediatric health is an important investment in a nation’s future. All of us at Roche are committed to enabling access to essential diabetes care for children with type 1 diabetes in the community, and helping them grow up to lead normal and healthier lives. We are pleased to partner with the VPA to support a continuum of care for children with T1D who need a helping hand under the Changing Diabetes® in Children programme.”

Mr. Hassan Fahmi, General Manager, Novo Nordisk Vietnam, said, “I am proud to represent Novo Nordisk today to witness the collaboration between Roche and the Vietnam Pediatric Association within the framework of CDiC. The collaboration lays down a sustainable foundation to support medical supplies; and empower children and families to continue driving change for kids with diabetes in Vietnam”.



1. IDF Atlas 2021 available at: https://www.diabetesatlas.org/en/resources


About Changing Diabetes® in Children (CDiC)
Changing Diabetes® in Children is a public-private partnership established in 2009. The partnership provides comprehensive care for children and young people living with Type 1 diabetes in low- and middle-income countries. This includes free life-saving medicine and supplies for young people with diabetes up to 25 years of age. The programme has to date provided free care to more than 41,000 children and youth living with Type 1 diabetes in low- and middle-income countries. In 2022, the partnership operated in 26 countries, in collaboration with global and local partners. To learn more, please visit Changing Diabetes in Children programme for children with type 1 diabetes (novonordisk.com) 

About the Vietnam Pediatric Association
The Vietnam Pediatric Association was established on April 29, 1961 under Decision No. 111/QD-NV of the Ministry of Home Affairs. From about 100 original members comprising pediatricians and doctors, over 60 years of growth and development, the Vietnam Pediatric Association has more than 1,200 members residing in 28 local pediatric associations and seven specialised branches today. As a social and professional organisation of pediatricians and those operating in the field of medical examination and treatment, teaching, research and disease prevention for children, the Vietnam Pediatric Association is the place to gather a team of medical professionals, specialists, and pediatricians for the cause of caring and protecting children's health in Vietnam.

For more information, please visit: http://hoinhikhoavn.com.


About Roche Diabetes Care
Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years. More than 4,500 employees in over 100 markets worldwide work every day to support people with diabetes and those at risk to achieve more time in their target ranges and experience true relief from the daily therapy routines.
Being a global leader in integrated Personalised Diabetes Management (iPDM), Roche Diabetes Care collaborates with thought leaders around the globe, including people with diabetes, caregivers, healthcare providers and payers. Roche Diabetes Care aims to transform and advance care provision and foster sustainable care structures. Under the brands RocheDiabetes, Accu-Chek and mySugr, comprising glucose monitoring, insulin delivery systems and digital solutions, Roche Diabetes Care unites with its partners to create patient-centred value. By building and collaborating in an open ecosystem, connecting devices and digital solutions as well as contextualising relevant data points, Roche Diabetes Care enables deeper insights and a better understanding of the disease, leading to personalised and effective therapy adjustments. For better outcomes and true relief.
Since 2017, mySugr, one of the most popular diabetes management apps, is part of Roche Diabetes Care.
For more information, please visit www.rochediabetes.com, www.accu-chek.com and www.mysugr.com.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.